Barriers to effective diagnosis and management of a bleeding patient with undiagnosed bleeding disorder across multiple specialties: results of a quantitative case-based survey

por Reding, Mark T, Cooper, David L
Publicado 2012

Use of recombinant human antithrombin concentrate in pregnancy

por Kreuziger, Lisa M Baumann, Prosen, Tracy L, Reding, Mark T
Publicado 2013

Target joint resolution in patients with haemophilia A receiving long‐term prophylaxis with BAY 94‐9027

por Reding, Mark T., Pabinger, Ingrid, Lalezari, Shadan, Santagostino, Elena, Mancuso, Maria Elisa
Publicado 2020

Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis

por Mancuso, Maria Elisa, Reding, Mark T., Negrier, Claude, Kerlin, Bryce A., Rangarajan, Savita, Simpson, Mindy L.
Publicado 2021

Prophylaxis use of clotting factor replacement products in people with non‐severe haemophilia: A review of the literature

por Iorio, Alfonso, Königs, Christoph, Reding, Mark T., Rotellini, Dawn, Skinner, Mark W, Mancuso, Maria Elisa, Berntorp, Erik
Publicado 2022

A laparoscopic approach to address massive splenomegaly, symptomatic cholelithiasis, and a planned postoperative pregnancy: A case report

por Bishop, Alexandra A., Krohn, Eric, Vakayil, Victor R., Pribyl, Kyle, Reding, Mark T., Tignanelli, Christopher, Harmon, James V.
Publicado 2023

Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study

por Reding, Mark T., Pabinger, Ingrid, Holme, Pål Andrè, Maas Enriquez, Monika, Mancuso, Maria Elisa, Lalezari, Shadan, Miesbach, Wolfgang, Di Minno, Giovanni, Klamroth, Robert, Hermans, Cedric
Publicado 2023

BAY 94‐9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results

por Lalezari, Shadan, Reding, Mark T., Pabinger, Ingrid, Holme, Pal Andre, Negrier, Claude, Chalasani, Pavani, Shin, Ho‐Jin, Wang, Maria, Tseneklidou‐Stoeter, Despina, Maas Enriquez, Monika
Publicado 2019

Confirmed long‐term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A: final results of the PROTECT VIII extension study

por Reding, Mark T., Pabinger, Ingrid, Holme, Pal Andre, Poulsen, Lone, Negrier, Claude, Chalasani, Pavani, Maas Enriquez, Monika, Wang, Maria, Meijer, Karina, Mancuso, Maria Elisa, Lalezari, Shadan
Publicado 2021

Integrated Hemophilia Patient Care via a National Network of Care Centers in the United States: A Model for Rare Coagulation Disorders

por Valentino, Leonard A, Baker, Judith R, Butler, Regina, Escobar, Miguel, Frick, Neil, Karp, Susan, Koulianos, Kollet, Lattimore, Susan, Nugent, Diane, Pugliese, Joseph N, Recht, Michael, Reding, Mark T, Rice, Michelle, Thibodeaux, Constance B, Skinner, Mark
Publicado 2021

Implementation of an Anticoagulation Practice Guideline for COVID-19 via a Clinical Decision Support System in a Large Academic Health System and Its Evaluation: Observational Stud...

por Shah, Surbhi, Switzer, Sean, Shippee, Nathan D, Wogensen, Pamela, Kosednar, Kathryn, Jones, Emma, Pestka, Deborah L, Badlani, Sameer, Butler, Mary, Wagner, Brittin, White, Katie, Rhein, Joshua, Benson, Bradley, Reding, Mark, Usher, Michael, Melton, Genevieve B, Tignanelli, Christopher James
Publicado 2021

Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study

por Kenet, Gili, Chen, Yeu-Chin, Lowe, Gillian, Percy, Charles, Tran, Huyen, von Drygalski, Annette, Trossaërt, Marc, Reding, Mark, Oldenburg, Johannes, Mingot-Castellano, Maria Eva, Park, Young-Shil, Peyvandi, Flora, Ozelo, Margareth C., Mahlangu, Johnny, Quinn, Jennifer, Huang, Mei, Reddy, Divya B., Kim, Benjamin
Publicado 2021

Persistence of Ad26.COV2.S‐associated vaccine‐induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies

por Kanack, Adam J., Singh, Bandana, George, Gemlyn, Gundabolu, Krishna, Koepsell, Scott A., Abou‐Ismail, Mouhamed Yazan, Moser, Karen A., Smock, Kristi J., Green, David, Major, Ajay, Chan, Clarence W., Wool, Geoffrey D., Reding, Mark, Ashrani, Aneel A., Bayas, Antonios, Grill, Diane E., Padmanabhan, Anand
Publicado 2022

PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with in...

por Escobar, Miguel, Luck, James, Averianov, Yevhenii, Ducore, Jonathan, Fernández, Maria Fernanda López, Giermasz, Adam, Hart, Daniel P., Journeycake, Janna, Kessler, Craig, Leissinger, Cindy, Mahlangu, Johnny, Martinez, Laura Villarreal, Miesbach, Wolfgang, Mitha, Ismail Haroon, Quon, Doris, Reding, Mark T., Schved, Jean‐François, Stasyshyn, Oleksandra, Vilchevska, Kateryna V., Wang, Michael, Windyga, Jerzy, Alexander, W. Allan, Al‐Sabbagh, Ahmad, Bonzo, Daniel, Mitchell, Ian S., Wilkinson, Thomas A., Hermans, Cédric
Publicado 2021